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Aims To determine whether changes in practice, over time, are associated with altered rates of major bleeding in acute
coronary syndromes (ACS).
Methods
and results
Patients from the Global Registry of Acute Coronary Events were enrolled between 2000 and 2007. The main outcome
measureswerefrequencyofmajorbleeding,includinghaemorrhagicstroke,overtime,afteradjustmentforpatientcharac-
teristics, and impact of major bleeding on death and myocardial infarction. Of the 50 947 patients, 2.3% sustained a major
bleed; almost half of these presented with ST-elevation ACS (44%, 513). Despite changes in antithrombotic therapy
(increasing use of low molecular weight heparin, P , 0.0001), thienopyridines (P , 0.0001), and percutaneous coronary
interventions (P , 0.0001), frequency of major bleeding for all ACS patients decreased (2.6 to 1.8%; P , 0.0001). Most
decline was seen in ST-elevation ACS (2.9 to 2.1%, P ¼ 0.02). The overall decline remained after adjustment for patient
characteristicsandtreatments(P ¼ 0.002,hazardratio0.94peryear,95%conﬁdenceinterval0.91–0.98).Hospitalcharac-
teristics were an independent predictor of bleeding (P , 0.0001). Patients who experienced major bleeding were at
increased risk of death within 30 days from admission, even after adjustment for baseline variables.
Conclusion Despite increasing use of more intensive therapies, there was a decline in the rate of major bleeding associated
with changes in clinical practice. However, individual hospital characteristics remain an important determinant of
the frequency of major bleeding.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Randomized trials and observational studies have reported that
patients who experience in-hospital bleeding are at higher risk of
in-hospital and later death after presentation with an acute coron-
ary syndrome (ACS).
1,2 Guidelines from the European Society of
Cardiology recommend that clinicians take into account the indi-
vidual patient’s risk of bleeding when selecting the optimal
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3 However, it is unclear whether more inten-
sive antithrombin and antiplatelet treatments and greater use of
angiography and percutaneous coronary intervention (PCI), over
time, may have increased the frequency of major bleeding.
By design, randomized trials exclude patients with extensive
comorbidity, hence large-scale studies with unbiased sample popu-
lations are required to deﬁne bleeding risk and their temporal
changes. The Global Registry of Acute Coronary Events
(GRACE) is the largest multinational study of patients with ACS
and has shown increasing use of invasive cardiac procedures and
antithrombotic strategies over an 8-year interval (2000–2007).
4
This change in practice was associated with improvements in clini-
cal outcome, notably reductions in death and new heart failure,
4
but it was unclear whether the beneﬁts in outcome were offset
by a greater frequency of bleeding.
The reported frequencies of major bleeding in large randomized
trials of ACS vary substantially
1,2,5–9 but inter-study comparisons
are confounded by differences in inclusion criteria and varying
deﬁnitions of bleeding.
10 Observational studies that include the
full spectrum of patients with an ACS and that apply consistent
criteria for bleeding may provide more reliable estimates of the
‘real world’ frequency of bleeding and changes over time. In the
GRACE study in 2003, in-hospital major bleeding rates (including
haemorrhagic stroke) ranged from 2.3% in patients with unstable
angina to 4.8% in those with ST-segment elevation myocardial
infarction (STEMI).
11 Patients with an acute myocardial infarction
who had a major in-hospital bleed tended to be older than
those who did not bleed, had more comorbid conditions, were
more likely to undergo interventional procedures, and had a
much higher in-hospital mortality rate (21% vs. 6%, P , 0.001).
12
For this report from the GRACE registry, we hypothesized that
changes in clinical practice over 8 years (more intensive antithrom-
botic and interventional therapy) would be accompanied by an
increased frequency of major bleeding. In addition, we aimed to
determine whether major bleeding impacted on the subsequent
rate of death or myocardial infarction, and we explored whether
variation in frequency of bleeding among hospitals is accounted
for by differences in the risk characteristics of patients.
Methods
The design, the standardized deﬁnitions, and the data-collection and
quality control methods for GRACE have been published else-
where.
13–15 GRACE is a prospective, multinational, observational,
cohort study of patients with ACS. GRACE is designed to reﬂect an
unselected population of patients with ACS, irrespective of geographic
region. A total of 123 hospitals located in 14 countries in North and
South America, Europe, Australia, and New Zealand have contributed
data to this study.
In brief, adult patients (18 or more years) admitted with a pre-
sumptive diagnosis of ACS at participating hospitals were potentially
eligible for this study. Eligibility required a clinical history of ACS
accompanied by at least one of the following: electrocardiographic
changes consistent with ACS, serial increases in biochemical
markers of cardiac necrosis (troponin, creatinine kinase MB, creati-
nine phosphokinase), and documented coronary artery disease.
Patients with non-cardiovascular causes for the clinical presentation,
such as trauma, surgery, or aortic aneurism, were excluded. Patients
were followed-up at 6 months by telephone, clinic visits, or
through calls to their primary care physician to ascertain the occur-
rence of several long-term outcomes. Where required, study investi-
gators received approval from their local hospital ethics or
institutional review board for the conduct of this study.
To enrol an unbiased sample of patients with ACS, sites were
encouraged to recruit the ﬁrst 10–20 consecutive eligible patients
each month. Training was conducted and regular audits performed
at all participating hospitals. Data were collected by trained study coor-
dinators using standardized case report forms. Demographic charac-
teristics, medical history, presenting symptoms, duration of
pre-hospital delay, biochemical and electrocardiographic ﬁndings,
treatment practices, and a variety of hospital outcome data were col-
lected. Standardized deﬁnitions of all patient-related variables, clinical
diagnoses, major bleeding, and hospital complications and outcomes
were used.
13 Major bleeding, including haemorrhagic stroke, was
deﬁned as life-threatening bleeding occurring in-hospital and requiring
a transfusion of  2 U of packed red blood cells or resulting in a
decrease in haematocrit of  10%, and/or resulting in death and/or
haemorrhagic stroke and/or subdural haematoma.
Patients were diagnosed with STEMI when they had new or pre-
sumed new ST-segment elevation  1 mm seen in any location, or
new left bundle branch block on the index or subsequent ECG with
at least one positive cardiac biochemical marker of necrosis (including
troponin measurements). In cases of NSTEMI at least one positive
cardiac biochemical marker of necrosis without new ST-segment
elevation seen on the index or subsequent ECG had to be present.
Unstable angina was diagnosed when serum biochemical markers
indicative of myocardial necrosis in each hospital’s laboratory were
within the normal range. Full deﬁnitions can be found on the
GRACE website at www.outcomes.org/grace. Hospital-speciﬁc feed-
back regarding patient characteristics, presentation, management, and
outcomes was provided to each centre on a quarterly basis in the
form of written reports.
This report is based on data from 50 947 patients with an ACS who
were enrolled at 123 hospitals in 14 countries between January 2000
and December 2007. Patients transferred in, patients with a discharge
diagnosis not related to ACS, and patients with bleeds related to coron-
ary artery bypass graft surgery were not included. Patients were categor-
ized at presentation into one of three categories for ST shift: new or
presumed new ST-elevation with or without ST-depression, new or pre-
sumed ST-depression alone, and no ST-wave segment change.
Statistical analysis
Baseline statistics for patients are given as frequencies and percentages
for categorical data; differences between those with and without
bleeds were tested using Fisher’s exact test. Continuous variables are
given as medians and 25th and 75th percentiles, and differences were
tested using a two-sided Wilcoxon rank-sum test. Cumulative bleeds
by type of ST-segment shift are presented as Kaplan–Meier plots.
For temporal trends, patients were assigned to 1 of 8 years based on
date of discharge or in-hospital death. Unadjusted linear trends in
in-hospital medication use, and outcomes, were assessed using a two-
sided Cochran-Armitage test at a ¼ 0.05. Post-discharge outcomes
were collected at 6 months after discharge and unadjusted linear
trends evaluated using the two-sided Cochran-Armitage test. The
number of patients followed for post-discharge events for year 8
was less than half that for the previous years due to the end of
patient enrolment. Data used for adjusted Cox proportional hazards
regression consider event status up to day 30 from hospitalization.
All statistical tests were performed at a ¼ 0.05 using SAS software
version 9.1 (SAS Institute Inc., Cary, NC, USA).
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Linear trends in major in-hospital bleeding were examined using a Cox
proportional hazards model adjusting for hospital and new or pre-
sumed new ST-wave change, and the following risk factors for bleed-
ing:
12 age, sex, glomerular ﬁltration rate (using the Modiﬁcation of Diet
in Renal Disease calculation), pulse, pulmonary artery catheter,
intra-aortic balloon pump, catheterization, PCI, ﬁbrinolytic therapy,
medical history (bleeding, peripheral arterial disease, atrial ﬁbrillation,
hypertension, and smoking), and medications given within the ﬁrst
24 h [intravenous glycoprotein IIb/IIIa inhibitors, intravenous inotropic
drugs, low molecular weight heparin (LMWH), unfractionated heparin
(UFH), and aspirin]. Catheterization, PCI, and ﬁbrinolytic therapy pre-
ceding major bleeds were included as time-varying covariates. The pro-
portional hazards assumption was checked by testing for the statistical
signiﬁcance of the interaction of each variable with the logarithm base
10 of the days to major bleed/haemorrhagic stroke/subdural haema-
toma. Statistically signiﬁcant interaction terms were retained in the
model.
Adjusted trends in outcomes and effect
of bleeding
Linear trends in all deaths and new myocardial infarctions (occurring
.24 h after presentation) up to 30 days from admission were adjusted
for patient characteristics and hospital procedures using Cox pro-
portional hazards regression. Since the date of new myocardial infarc-
tions was available from 2003 onwards, adjusted temporal trends were
examined for 2003–2007, whereas adjusted trends for 30-day death
covered the years 2000–2007. Linear trends for post-discharge
deaths and myocardial infarctions up to 180 days from admission
were for 2000–2007 and 2003–2007, respectively.
Cox regression candidate variables for both 30-day outcomes
included the GRACE risk variables for in-hospital death
16 [age, Killip
class (continuous variable), systolic blood pressure, pulse, serum crea-
tinine, cardiac arrest during presentation, positive initial cardiac
markers, ST-segment shift category], major bleed status, year of dis-
charge or death, and hospital; and catheterization, PCI, and ﬁbrinolytic
status as time-varying covariates. Adjusted trends in post-discharge
death and myocardial infarction for patients surviving hospitalization
were similarly examined using Cox regression, the same candidate vari-
ables, and additionally, medical histories of congestive heart failure,
peripheral arterial disease, and myocardial infarction. The proportional
hazards assumption was checked for all models by testing for the stat-
istical signiﬁcance of the interaction of each variable with the logarithm
base 10 of the days-to-event. Statistically signiﬁcant interaction terms
were retained in the models.
Hazard ratios (HRs) comparing patients with major bleeds/haemor-
rhagic stroke to patients without were computed to assess the effect
of bleeding on outcomes. The effect on 30-day death differed by
ST-segment shift category, whereas the effect of bleeding on 30-day
myocardial infarctions and post-discharge outcomes did not.
Results
Of the 50 947 patients in the study, 2.3% (n ¼ 1160) sustained a
major bleed. Of those with a major bleed, 513 (44%) presented
with ST-elevation ACS, 296 (26%) presented with ST-depression
ACS, and in 351 (30%) there was no ST-deviation at presentation.
Patients who bled were older than those who did not bleed and a
greater proportion were women (Table 1). When compared with
those without a bleed, patients who bled had higher rates of prior
atrial ﬁbrillation, congestive heart failure, diabetes, transient
ischaemic attack/stroke, peripheral arterial disease, and hyper-
tension, but lower rates of current or former smoking and hyper-
lipidaemia. Patients with a bleed had a higher GRACE risk score
for hospital mortality and presented with higher heart rates,
more heart failure (Killip classes II–IV), and more had sustained
a cardiac arrest (Table 1). Patients with a bleed were more likely
than those without to have undergone cardiac catheterization,
PCI, or to have received ﬁbrinolytic therapy during hospitalization
(Table 1).
Red blood cell transfusion was undertaken in 57% of all major
bleeds. The median number of red blood cell units transfused
within the ﬁrst 24 h after a bleed was 2.0 (interquartile range 1–
2). The median total number of red blood cell units transfused
after a bleed was 2.0 (interquartile range 2–3).
Trends in the management of acute
coronary syndrome
Table 2 shows temporal trends in the medical management of all
ACS patients since 2000. The use of antithrombotic therapies
changed, with a fall in the use of UFH and increasing use of
LMWH for all types of ACS (P , 0.0001 for linear trend). For all
types of ACS, the use of a thienopyridine within 24 h of presen-
tation also increased (P , 0.0001 for linear trend). Overall use of
glycoprotein IIb/IIIa inhibitors among all ACS patients did not
change over time. Among patients with ST-elevation, use of GP
IIb/IIIa inhibitors decreased for those who underwent any PCI,
including primary PCI (P , 0.0001 for linear trend) (Table 2).
Figure 1 shows temporal trends in the use of selected interven-
tions and ﬁbrinolysis for ACS since 2000. Use of PCI has increased,
particularly for patients with ST-segment elevation ACS (P ,
0.0001 for linear trend), whereas the use of ﬁbrinolytic drugs in
this patient group has decreased (P , 0.0001 for linear trend).
Temporal trends in major bleeding
In the overall ACS population, the rates of bleeding decreased over
the study period (Table 3). This decline was also observed in the
population with ST-depression and in those with no ST shift.
Kaplan–Meier cumulative rates of bleeding from hospital admission
up to 15 days are shown in Figure 2. Patients with ST-segment
elevation were at greatest risk of ‘early’ bleeding (admission to
6 days). The rate of major bleeding increased steadily for patients
with ST-segment depression, exceeding that in the ST-elevation
group after 6 days. Individuals with neither ST-elevation nor
depression remained at lowest risk of major bleeding.
Unadjusted temporal trends in the rates of major bleeding since
2000, according to type of ST-segment shift, are shown in Figure 3.
Among all ACS patients, major bleeding decreased from 2.6% to
1.8% (P , 0.0001) (Table 3). Among patients with ST-segment
elevation ACS, major bleeding decreased from 2.9% to 2.1%
(P ¼ 0.02), whereas there was no change among patients with
ST-segment depression ACS. Among patients with no ST-segment
shift, major bleeding decreased from 2.0 to 1.5% (P , 0.001).
After Cox proportional hazards adjustment for patient charac-
teristics, medications, and interventions, the downward temporal
trend in bleeding remained for all ACS (HR 0.94 per year, 95%
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Table 1 Patients’ baseline characteristics, according to bleeding status
Patients without a bleed (n 5 49 787) Patients with a bleed (n 5 1160) P-value
a
Age
b (years) 67 (56–76) 74 (65–81) ,0.0001
Men (%) 33 332 (67) 615 (53) ,0.0001
Medical history (%)
Angina 25 583 (52) 568 (49) 0.10
Atrial ﬁbrillation 3904 (7.9) 127 (11) ,0.001
Congestive heart failure 5094 (10) 196 (17) ,0.0001
Coronary angiography 15 800 (32) 327 (29) 0.014
Diabetes 12 428 (25) 349 (30) ,0.0001
Myocardial infarction 15 073 (30) 352 (31) 0.92
Positive stress test 5312 (11) 102 (8.9) 0.043
Transient ischaemic attack/stroke 4137 (8.4) 121 (11) 0.010
Smoker (current/former) 28 035 (57) 598 (52) 0.001
Peripheral arterial disease 4516 (9.1) 179 (16) ,0.0001
Hypertension 30 922 (63) 790 (68) ,0.0001
Hyperlipidaemia 24 019 (49) 515 (45) ,0.01
CABG 6265 (13) 139 (12) 0.62
PCI 9035 (18) 178 (16) 0.017
Clinical presentation
Pulse
b (b.p.m.) 76 (65–90) 82 (70–99) ,0.0001
Systolic BP
b (mmHg) 140 (120–160) 137 (115–160) ,0.0001
Diastolic BP
b (mmHg) 80 (70–90) 76 (62–89) ,0.0001
Glomerular ﬁltration rate 71 (55–86) 58 (41–75) ,0.0001
Cardiac arrest (%) 941 (1.9) 43 (3.8) ,0.0001
Killip class (%)
I 40 754 (84) 813 (71) ,0.0001
II 5762 (12) 214 (19) ,0.0001
III 1816 (3.7) 88 (7.7) ,0.0001
IV 445 (0.9) 27 (2.4) ,0.0001
Positive cardiac biomarkers (%) 22 496 (46) 628 (55) ,0.0001
Initial serum creatinine
b (mg/dL) 1.0 (0.9–1.3) 1.1 (0.9–1.5) ,0.0001
Initial glucose
b (mg/dL) 125 (103–166) 143 (113–191) ,0.0001
Fasting glucose
a (mg/dL) 104 (92–130) 111 (95–140) ,0.0001
GRACE risk score
b 144 (122–169) 169 (144–192) ,0.0001
Type of ACS (%)
STEMI 17 349 (35) 530 (46) ,0.0001
NSTEMI 16 811 (34) 437 (38) ,0.01
Unstable angina 15 627 (31) 193 (17) ,0.0001
Type of ST shift (%)
ST-elevation 18 242 (37) 513 (44) ,0.0001
ST-depression 8949 (18) 296 (26) ,0.0001
No shift 22 596 (45) 351 (30) ,0.0001
In-hospital procedures (%)
Cardiac catheterization 29 089 (59) 747 (65) ,0.0001
PCI 17 907 (36) 559 (49) ,0.0001
Fibrinolytic drugs 5995 (12) 161 (14) ,0.01
CABG 2248 (4.6) 29 (2.5) ,0.0001
ACS, acute coronary syndrome; BP, blood pressure; CABG, coronary artery bypass grafting; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous
coronary intervention; STEMI, ST-segment elevation myocardial infarction.
aTwo-sided Fisher’s exact test for binomial variables and two-sided Wilcoxon rank-sum test for continuous variables.
bMedian (interquartile range).
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ST-depression (HR 0.93, 95% CI 0.86–1.0) and in those with no
ST shift (HR 0.91, 95% CI 0.85–0.97).
Do hospital characteristics inﬂuence the
frequency of bleeding?
When hospitals were divided into quintiles according to median
rates of major bleeds, the rate ranged from 0.4% to 4.1%, repre-
senting a 10-fold difference between the highest and lowest
quintiles (Figure 4). Despite adjustment for patient characteristics,
treatments, and interventions, individual hospitals remained an
independent predictor of bleeding (P , 0.0001).
Impact of major bleeding on mortality
and (re)infarction
In the overall ACS population, patients who experienced a major
bleed were at increased risk of 30-day death (HR 2.0, 95% CI
1.7–2.4; Figure 5). This ﬁnding was most pronounced among
patients with no ST-segment shift, with the HR increasing
three-fold even after adjustment for baseline variables and inter-
ventions (catheterization, PCI, ﬁbrinolytics) (HR 3.0, 95% CI
2.2–4.1).
In patients who experienced a major bleed, there was an associ-
ation with (re)infarction (HR 2.0, 95% CI 1.4–2.8, P ¼ 0.0001).
However, 10 of the 724 bleeds occurred after the infarction.
The association between bleeding and subsequent (re)infarction
showed a trend for increased hazard (HR 1.4, 95% CI 1.0–2.1;
Figure 4).
Discussion
These data, from the largest multinational observational study of
patients presenting to hospital for an ACS, show that despite
increasing use of more aggressive interventional and pharmacologi-
cal therapies, there has been a statistically signiﬁcant downward
trend in the rates of major bleeding (P , 0.0001) between 2000
and 2007. The decline in bleeding mirrors that for death and
heart failure reported in an earlier study from the GRACE
registry.
4
Although it may have been expected that the frequency of major
bleeding would have increased over time on account of more
potent antithrombotic therapies and antithrombotic combinations
(substitution of LMWH for UFH, greater use of thienopyridines
and GP IIb/IIIa inhibitors) and greater use of cardiac catheterization
and PCI, in fact the converse was found. These ﬁndings suggest that
other changes in clinical practice have contributed to the reduction
in bleeding frequency (e.g. improved instrumentation for cardiac
catheterization, smaller calibre catheters, increasing use of radial
access, possibly improved accuracy of dosing of parenteral anti-
thrombotics, physician awareness of bleeding, reduction in the
use of glycoprotein IIb/IIIa inhibitors, and changing thresholds for
transfusion).
...............................................................................................................................................................................
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Table 2 Temporal trends in the medical management of (within ﬁrst 24 h) and selected interventions for ACS since
2000
Treatment 2000 2001 2002 2003 2004 2005 2006 2007 P-value
All ACS (n) 7050 7068 7343 7477 7014 5831 5276 3888
Aspirin (%) 89 90 90 88 89 91 91 91 ,0.002
GP IIb/IIIa inhibitor (%) 15 17 20 20 16 18 19 15 0.95
LMWH (%) 37 41 50 55 55 56 56 63 ,0.0001
Unfractionated heparin (%) 48 44 39 34 31 31 32 24 ,0.0001
Thienopyridine (%) 14 22 35 41 46 56 59 65 ,0.0001
ST-elevation (n) 1405 2635 2677 2856 2597 2059 1769 1268
GP IIb/IIIa inhibitor
a with PCI (%)
Primary PCI 64 75 73 65 49 56 53 46 ,0.0001
Other PCI 25 28 32 30 21 17 21 18 ,0.0001
Any PCI 42 50 54 50 39 41 44 38 ,0.0001
No PCI 6.2 5.6 5.7 7.3 5.6 6.1 5.8 4.8 0.68
ACS, acute coronary syndrome; GP, glycoprotein; LMWH, low molecular weight heparin; PCI, percutaneous coronary intervention.
aDenominator is the number of patients in each PCI category.
Figure 1 Temporal trends in cardiac procedures in all patients
with an ACS, in patients with ST-segment elevation, ST-segment
depression, or no ST shift, and ﬁbrinolysis in patients with
ST-elevation ACS.
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especially in some regions and some countries, but these changes
are not sufﬁcient to account for the observed decline in bleeding
frequency. The use of radial access was low, for almost all
countries, during the time period reported in this study. For
example, according to the ACC-NCDR registry in the USA, in
the fourth quarter of 2008 the national rate of radial procedures
in the USA was only 1.6%. As similar declines in bleeding were
observed in the USA compared with other countries, it is unlikely
that radial access can account for the major part of the decline in
bleeding. Physician awareness of bleeding has increased over the
study period and this may have contributed to a decline in the
threshold for transfusion.
We have demonstrated previously that the risk proﬁle of the
GRACE ACS population has not declined over time (it remained
unchanged for ST-elevation ACS and increased for ST-depression
ACS),
4 and the changes in bleeding in this report take account of
the risk score over time. For patients presenting with ST-elevation,
there was a downward trend in the frequency of bleeding (P ,
0.0001); for those presenting with ST-depression there was no
change in bleeding frequency; and in those without ST-deviation
there was a downward trend (P ¼ 0.06).
Nevertheless, when major bleeding occurred it was associated
with a subsequent risk of death and of myocardial infarction, and
this risk is of similar magnitude to that seen in the previous clinical
trials.
5,17,18 The data also show that major bleeding is associated
with a three-fold increase in the risk of death in patients with no
ST shift and a two-fold increase in those with ST-elevation. An
...............................................................................................................................................................................
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Table 3 Raw bleeding rates by year, and unadjusted and risk-adjusted hazard ratios
2000 2001 2002 2003 2004 2005 2006 2007 P-value for
linear trend,
unadjusted
Hazard ratio
a*,
unadjusted (95% CI)
Hazard ratio
a,
adjusted
b (95% CI)
All ACS
% 2.6 2.7 2.5 2.2 2.5 1.9 1.7 1.8 ,0.0001 0.96 (0.93–0.98) 0.94 (0.91–0.98)
Number with bleed 181 193 181 162 174 110 88 71
ST-elevation
% 2.9 3.4 2.9 2.4 2.8 2.5 2.4 2.1 0.02 0.97 (0.93–1.01) 0.98 (0.93–1.0)
Number with bleed 74 93 80 71 73 52 43 27
ST-depression
% 3.3 2.9 4.0 3.3 3.8 2.3 2.8 2.4 0.19 0.98 (0.93–1.04) 0.93 (0.86–1.0)
Number with bleed 46 38 53 47 48 24 25 15
No ST shift
% 2.0 2.0 1.5 1.4 1.7 1.3 0.8 1.5 ,0.001 0.93 (0.89–0.98) 0.91 (0.85–0.97)
Number with bleed 61 62 48 44 53 34 20 29
Major bleeding was classiﬁed as contributing to death in 12% of major bleeds; classiﬁed as clinically overt within a critical organ (intracranial, retroperitoneal, intraocular, adrenal,
spinal, pericardial) in 16%; was clinically overt, leading to a transfusion of two or more units of packed red blood cells in 49%; was associated with a fall in haemoglobin of 2 g/dL or
more in 58% (GRACE bleeding substudy).
aPer year.
bAdjusted for patient characteristics, medications, and interventions.
Figure 2 Kaplan–Meier plot of major bleeds and/or haemor-
rhagic stroke and/or subdural haematoma from hospital admis-
sion up to 15 days in patients with ST-segment elevation,
ST-segment depression, or neither. Figure 3 Temporal trends in the rates of major bleeding and/or
haemorrhagic stroke and/or subdural haematoma, in patients with
ST-segment elevation, ST-segment depression, or neither.
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two-fold increase in the risk of 30-day myocardial (re)infarction.
However, 10 of 724 bleeds occurred after the infarction, resulting
in a 1.4-fold hazard (95% CI 1.0–2.1) of bleeding with subsequent
infarction.
To explore whether hospital characteristics may be associated
with variations in the frequency of bleeding, all models were
adjusted for individual hospitals as well as baseline patient
characteristics. Even after adjustment for patient characteristics,
treatments, and interventions, the overall P-value for hospitals
was still statistically signiﬁcant (P , 0.0001). Hospitals were also
divided into quintiles according to bleeding frequency. The
median unadjusted rate of bleeding among hospitals in the
highest quintile was 10 times the median rate among hospitals
in the lowest quintile (Figure 4). These ﬁndings suggest that
hospital-dependent variables may have an important impact upon
the risk of major bleeding. Individual hospital variables are likely
to be the consequence of differences in practice patterns, and
potentially amenable to change.
Strengths and limitations
GRACE employed standard deﬁnitions for outcome events includ-
ing myocardial infarction and major bleeding (rather than centre-
or clinician-dependent criteria), so changes in bleeding frequency
do not represent changes in diagnostic criteria or diagnostic
threshold for bleeding. The rates of major bleeding are of similar
magnitude to those reported for large-scale trials of ACS
patients
5,9,19,20 but lower than those reported in trials that
include haematoma in the deﬁnition of major bleeding.
17 Our deﬁ-
nition of haemorrhagic stroke includes subdural haematoma.
GRACE is a non-randomized, observational study; in common
with other observational studies, it may be subject to potential
biases, including the collection of non-randomized data, missing
or incomplete information, and potential confounding by drug indi-
cation or other unmeasured covariates. Such confounding would
be of particular relevance if non-randomized treatments were
compared, but is not relevant to the time-dependent analyses.
GRACE included a large systematic patient cohort and the group
comparisons were determined by the presence or absence of
ST-deviation at presentation, rather than treatment-dependent
variables. Outcomes were not analysed by ﬁnal hospital discharge
diagnosis (e.g. myocardial infarction or no myocardial infarction) as
Figure 4 Hospitals divided into quintiles according to percen-
tage of in-hospital bleeds (ﬁgure; data show medians, minimum
and maximum values; 17 or 18 hospitals per quintile) and
in-hospital death (table). All data are derived from hospitals
that provided bleeding status in  100 patients.
Figure 5 Risk of 30-day death (2000–2007; n ¼ 45 406 patients with an acute coronary syndrome) and 30-day myocardial (re)infarction
(2003–2007; n ¼ 26 126), adjusted for GRACE risk variables and treatment interventions (catheterization, PCI, ﬁbrinolytics): patients with
vs. without a major bleed and/or haemorrhagic stroke and/or subdural haematoma.
Improved frequency of bleeding in ACS patients 673such outcome events may have evolved during the hospital stay.
GRACE is more representative of clinical practice than a trial
population as those with co-morbidity or advanced age were not
excluded and this study is likely to reﬂect the frequency of bleeding
over time in an unselected population of patients presenting with
ACS.
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Rare angiographic and echocardiographic ﬁndings of an aortic arch
interruption in a patient with differential cyanosis
Sarinya Puwanant1,2*, Suphot Srimahachota1,2, Kachon Yanyong1,2, and Smonporn Boonyaratavej1,2
1Division of Cardiology, Department of Medicine, Faculty of Medicine, Chulalongkorn University; and
2King Chulalongkorn Memorial Hospital, Thai Red Cross Society,
Bangkok 10330, Thailand
*Corresponding author. Tel. þ66 836566651, Email: sarinyausmle@yahoo.com
A 23-year-old lady with a 3-year history of undiagnosed
murmur and progressive dyspnoea was referred to our
institution for a percutaneous patent ductus arteriosus
(PDA) closure. Physical examination revealed differen-
tial cyanosis with an oxygen saturation in the upper
and lower extremity of 95 and 86%, respectively. A
loud P2 with a grade 3/6 systolic murmur was audible
at the second left intercostal space with radiation to
the back. An echocardiogram revealed a non-restrictive
ventricular septal defect (Panel A, arrow) with an over-
riding aorta and a large PDA (Panel B, arrow) with a
diminished diastolic ﬂow. A suprasternal view demon-
strated an aortic arch interruption (type A) (Panel C)
and aortic discontinuity distal to the left subclavian
artery. A left ventriculography conﬁrmed an inter-
rupted aortic arch with a clear separation between
three branches of aortic arch and the descending
aorta (Panel D). A right heart catheterization revealed
severe ﬁxed pulmonary hypertension with a mean pul-
monary artery pressure of 92 mmHg and pulmonary
vascular resistance of 11 Woods units. Since the
patient had ﬁxed pulmonary hypertension, the surgical
correction was unfortunately not performed. The patient was then referred to heart and lung transplantation.
This case highlights the essence of left heart or aortic obstruction, i.e. interrupted aortic arch or coarctation of the aorta, when PDA
is discovered. Failure to identify aortic arch interruption in this case of attempted PDA closure will lead to catastrophic lower-half
ischaemia.
Panels A–D. Asc Ao, ascending aorta; CC, left common carotid artery; DAO, descending aorta; LV, left ventricle; LSC, left subclavian
artery; mPA, main pulmonary artery; PDA; patent ductus arteriosus; Inn, innominate artery, VSD, ventricular septal defect; RV, right
ventricle.
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